Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Receivables: 2021-2024

Historic Change in Receivables for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $20.5 million.

  • Kiniksa Pharmaceuticals International's Change in Receivables rose 346.97% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 22.92%. This contributed to the annual value of $20.5 million for FY2024, which is 137.72% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Change in Receivables of $20.5 million as of FY2024, which was up 137.72% from $8.6 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Change in Receivables ranged from a high of $20.5 million in FY2024 and a low of $3.9 million during FY2021.
  • Moreover, its 3-year median value for Change in Receivables was $8.7 million (2022), whereas its average is $12.6 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first declined by 0.80% in 2023, then skyrocketed by 137.72% in 2024.
  • Kiniksa Pharmaceuticals International's Change in Receivables (Yearly) stood at $3.9 million in 2021, then surged by 121.87% to $8.7 million in 2022, then decreased by 0.80% to $8.6 million in 2023, then skyrocketed by 137.72% to $20.5 million in 2024.